Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Site-active steroid provides symptomatic relief for patients with dry eye disease
Miami—Anti-inflammatory treatment using loteprednol etabonate suspension 0.2% (Alrex, Bausch & Lomb) appears to offer a safe and useful option for symptomatic relief in patients with dry eye, according to Roberto Beraja, MD.
Related Videos
Related Content
